Physician
Ismail Ozcan MD PC
Ismail Ozcan MD PC was paid $6.48M by Medicaid between Jan 2018 and Nov 2024, across 71 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 55% of everything it billed.
33Billing provider infoISMAIL OZCAN MD PC
LAKE RONKONKOMA, NY 11779
LAKE RONKONKOMA, NY 11779
33aNPI1518082080assigned 03/21/2007
33bProvider typeFamily Medicine Physician
28Total paid$6.48M
24GClaims125,591
24DCodes billed71
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Family Medicine Physician providers in New York
Rank by total paid#22 of 2,605
Median peer was paid$10K
This provider vs. median642×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,942 | $492K | |
| 2019 | 10,729 | $552K | |
| 2020 | 16,161 | $829K | |
| 2021 | 24,896 | $1.29M | |
| 2022 | 23,928 | $1.21M | |
| 2023 | 22,433 | $1.25M | |
| 2024incomplete | 16,502 | $860K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 55% | 39,596 | 29,018 | $3.54M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 17,996 | 14,436 | $1.07M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.4% | 1,967 | 1,959 | $283K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 3.8% | 2,493 | 2,465 | $245K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 3.0% | 411 | 258 | $198K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.0% | 3,551 | 2,498 | $130K |
| 93880 | 1.9% | 1,108 | 1,104 | $124K | |
| 87428 | 1.9% | 2,939 | 2,601 | $120K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.6% | 1,128 | 1,118 | $104K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.3% | 439 | 401 | $87K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 4,065 | 3,554 | $66K |
| 93000 | <1% | 5,292 | 5,231 | $60K |
59 more codes
| 87631 | <1% | 862 | $58K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,266 | $47K |
| 99401 | <1% | 2,447 | $41K | |
| 95117 | <1% | 3,021 | $31K | |
| 87807 | <1% | 3,395 | $30K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,501 | $28K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,601 | $27K |
| 99051 | <1% | 4,905 | $23K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 131 | $16K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 139 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 306 | $10K |
| 90686 | <1% | 538 | $9K | |
| 90674 | <1% | 330 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,129 | $9K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 443 | $8K |
| 93015 | <1% | 160 | $7K | |
| 82947 | <1% | 2,305 | $7K | |
| 90670 | <1% | 36 | $7K | |
| 90688 | <1% | 432 | $7K | |
| 94010 | <1% | 310 | $7K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 135 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 164 | $6K |
| G0008 | Administration of influenza virus vaccine | <1% | 645 | $5K |
| 0064A | <1% | 131 | $4K | |
| 90677 | <1% | 13 | $4K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 834 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,672 | $3K |
| 0011A | <1% | 98 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,192 | $3K |
| 0012A | <1% | 63 | $2K | |
| 93351 | <1% | 14 | $2K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,183 | $2K |
| 0002A | <1% | 54 | $2K | |
| 0001A | <1% | 50 | $2K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 195 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 225 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 369 | $1K |
| 81002 | <1% | 684 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,048 | $987.60 |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 12 | $967.90 |
| 92567 | <1% | 92 | $961.87 | |
| 90746 | <1% | 12 | $827.25 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 16 | $734.61 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 279 | $637.49 |
| G0009 | Administration of pneumococcal vaccine | <1% | 47 | $468.83 |
| G9226 | Foot examination performed (includes examination through visual inspection, sensory exam with 10-g monofilament plus testing any one of the following: vibration using 128-hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold, and pulse exam; report when all of the 3 components are completed) | <1% | 30 | $262.50 |
| 99173 | <1% | 131 | $225.46 | |
| 99406 | <1% | 13 | $152.31 | |
| 86308 | <1% | 25 | $91.03 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 13 | $85.00 |
| 83014 | <1% | 112 | $44.36 | |
| 99072 | <1% | 193 | $33.24 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 146 | $5.59 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 20 | $1.92 |
| 91306 | <1% | 111 | $0.06 | |
| 91300 | 0% | 95 | $0.00 | |
| 91301 | 0% | 206 | $0.00 | |
| 91307 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOZCAN, ISMAIL (OWNER)